Eli Lilly Pullback Presents a Buying OpportunityEli Lilly and CompanyBATS:LLYfinvestnomicsLLY is beginning to attract buying interest after retracing to its 20-day moving average. The stock remains in a strong uptrend, continuing to make higher highs and higher lows while trading above its well-aligned 20- and 50-day moving averages. Eli Lilly & Co. is a $1.13 trillion market cap pharmaceutical company engaged in the discovery, development, manufacture, and sale of innovative medicines. Its portfolio spans key therapeutic areas, including diabetes, oncology, immunology, neuroscience, and other specialty treatments, supported by a robust research and development pipeline. LLY is a wide economic moat company that has delivered significant revenue and EPS growth over the last three quarters. The company continues to generate exceptional profitability, with operating and net margins of 49% and 37%, respectively. It also demonstrates outstanding capital efficiency, producing ROE of 108% and ROIC of 42%, while maintaining a solid financial position with current and debt-to-equity ratios of 1.5x and 1.4x, respectively.